TNGX Stock Hits Record High on Inking Collaboration Deal With ERAS

Key Takeaways TNGX shares surged 36.3% to a record high after ERAS announced a clinical trial collaboration and supply deal.ERAS will supply ERAS-0015 while TNGX sponsors a phase I/II combo study in MTAP-deleted RAS-mutant cancers.TNGX plans to initiate a pivotal study of vopimetostat monotherapy in MTAP-deleted pancreatic cancer in 2026.Shares of Tango Therapeutics (TNGX) surged 36.3% on Thursday to a record high after Erasca (ERAS) announced a clinical trial collaboration and supply agreement with the com ...